Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

1993 • 3,859 citations

Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease

1995 • 3,549 citations

Nonparametric Statistical Methods.

1974 • 2,964 citations

A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory Questionnaire

1992 • 2,933 citations

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

1999 • 2,553 citations

Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

1998 • 2,273 citations

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

2000 • 1,684 citations

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

1995 • 1,618 citations

Applied Mixed Models in Medicine

2000 • 1,291 citations

Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking

1999 • 1,057 citations

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1999 • 833 citations

Guidelines for the management of chronic obstructive pulmonary disease

2002 • 604 citations

Efficacy of Salmeterol Xinafoate in the Treatment of COPD

1999 • 532 citations

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease

1998 • 517 citations

Quality of life changes in COPD patients treated with salmeterol.

1997 • 505 citations

Scientific rationale for inhaled combination therapy with long-acting β₂-agonists and corticosteroids

2002 • 447 citations

Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease

2001 • 364 citations

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

1997 • 359 citations

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1997 • 278 citations

Use of a Long-acting Inhaled β₂-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease

2001 • 269 citations

Comparison of the Efficacy, Tolerability, and Safety of Formoterol Dry Powder and Oral, Slow-Release Theophylline in the Treatment of COPD

2002 • 258 citations

Reliability and validity of the chronic respiratory questionnaire (CRQ).

1994 • 214 citations

BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease

1997 • 213 citations

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

1999 • 173 citations

Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD

2001 • 157 citations

Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation.

1992 • 147 citations

Exercise Capacity Predicts Health Status in α₁-Antitrypsin Deficiency

2001 • 66 citations

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease

1998 • 49 citations

Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.

1999 • 17 citations

Cited By (0)

Loading...